论文部分内容阅读
据两项多中心研究结果的初步分析表明，GileadSciences公司正在进行皿期临床研究的adefovirdipioxi（商品名Preveon），在60mg剂量下对HIV感染有一定的疗效。在第一项多中心研究中，47例末经任何治疗的HIV感染者随机口服本品60mg-日1次或安慰剂，治疗4周，结果本品组的抗病毒活
Preliminary analyzes of two multicentre studies suggest that adefovirdipioxi (brand name Preveon) undergoing a phase III clinical trial by Gilead Sciences has a dose-response to HIV infection at 60 mg. In the first multicenter study, 47 HIV-infected individuals who had undergone any treatment were randomized to receive 60 mg of the product once daily or placebo for 4 weeks, resulting in antiviral activity in this product group